JAMA Neurol: The relationship between the use of enzyme-induced antiepileptic drugs and long-term cardiovascular disease

Epilepsy Patients suffering from heart blood vessels at high risk of the disease
.

Compared with the general population, ischemic heart disease, transient ischemic attack, cerebral ischemic stroke and hemorrhagic stroke, which may be part of the epilepsy itself, sedentary behavior, high smoking rates, lower socioeconomic status , Obesity is related to self-reported health conditions

Epilepsy Patients suffering from heart blood vessels at high risk of the disease

Anti-epileptic drugs (ASM), especially enzyme-induced ASM (EIASM) may also work

Recently, some researchers have quantified and modeled the postulated risk of cardiovascular disease after the use of EASM

This cohort study covered the period from January 1990 to March 2019 (median [IQR] follow-up, 9 years [4-15 years])
.

This study links the primary care of the National Health Service in the UK with the hospital's electronic health records

This cohort study covered the period from January 1990 to March 2019 (median [IQR] follow-up, 9 years [4-15 years])

After the diagnosis of adult onset (age ≥ 18 years) epilepsy or repeated exposure in the weighted cumulative exposure model, consecutively received 4 EASMs (carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, Primidone, rufenamide or topiramate)

Three cohorts were isolated.

• Among 10,916,166 adults, 50,888 (0.
  
  Patients receiving EASM treatment have a higher risk of cardiovascular disease
  
  Literature source: https://jamanetwork-com.
  washington.
  80599.
  net/journals/jamaneurology/fullarticle/2784443?resultClick=1 https://jamanetwork-com.
  washington.
  80599.
  net/journals/jamaneurology/fullarticle/2784443? resultClick=1 leave a message here